The scientist’s investigation covers issues in Ankylosing spondylitis, Internal medicine, Spondylitis, Immunology and Surgery. His Ankylosing spondylitis study incorporates themes from Psoriatic arthritis, Infliximab, Physical therapy, Severity of illness and Etanercept. Internal medicine is closely attributed to Gastroenterology in his work.
His research on Spondylitis also deals with topics like
Robert D. Inman mainly focuses on Ankylosing spondylitis, Immunology, Internal medicine, Arthritis and Physical therapy. His specific area of interest is Ankylosing spondylitis, where he studies Spondylitis. His studies in Immune system, Reactive arthritis, Antigen, Pathogenesis and Human leukocyte antigen are all subfields of Immunology research.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery. His research integrates issues of Back pain and Axial spondyloarthritis in his study of Physical therapy. His work carried out in the field of Placebo brings together such families of science as Golimumab and Randomized controlled trial.
His primary scientific interests are in Ankylosing spondylitis, Immunology, Internal medicine, Axial spondyloarthritis and Spondylitis. Robert D. Inman interconnects Physical therapy, BASDAI and Disease, Inflammatory bowel disease in the investigation of issues within Ankylosing spondylitis. Monocyte, Signal transduction and Chlamydia muridarum is closely connected to Receptor in his research, which is encompassed under the umbrella topic of Immunology.
His Internal medicine research includes elements of Gastroenterology, Placebo, Surgery and Default mode network. His Axial spondyloarthritis course of study focuses on Quality of life and Somewhat Worse, Ankylosing Spondylitis Quality of Life and Receiver operating characteristic. As a part of the same scientific family, Robert D. Inman mostly works in the field of Spondylitis, focusing on Back pain and, on occasion, Biomarker and Patient advocacy.
Ankylosing spondylitis, Immunology, Spondylitis, Physical therapy and Chronic pain are his primary areas of study. Ankylosing spondylitis is a primary field of his research addressed under Internal medicine. His Immunology research is multidisciplinary, relying on both Receptor and Cell migration.
The various areas that Robert D. Inman examines in his Spondylitis study include Transcription factor, HLA-B27, Immune system and Medical genetics. His Physical therapy research is multidisciplinary, incorporating elements of Adalimumab, Psoriatic arthritis, Infliximab, Axial spondyloarthritis and Evidence-based medicine. His studies deal with areas such as Resting state fMRI, Default mode network and Brain mapping as well as Chronic pain.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde;Sofia Ramiro;Robert Landewé;Xenofon Baraliakos.
Annals of the Rheumatic Diseases (2017)
ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Zochling;D. Van Der Heijde;R. Burgos-Vargas;E. Collantes.
Annals of the Rheumatic Diseases (2006)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal
M Rudwaleit;R Landewé;D van der Heijde;J Listing.
Annals of the Rheumatic Diseases (2009)
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
John C. Davis;Désirée Van Der Heijde;Jurgen Braun;Maxime Dougados.
Arthritis & Rheumatism (2003)
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
D M Evans;Spencer Cca.;J J Pointon;Z Su.
Nature Genetics (2011)
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Robert D. Inman;John C. Davis;Désirée Van Der Heijde;Laura Diekman.
Arthritis & Rheumatism (2008)
Molecular Mimicry and Autoimmunity
Lori J. Albert;Robert D. Inman.
The New England Journal of Medicine (1999)
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.
A Cortes;J Hadler;J P Pointon.
Nature Genetics (2013)
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci
John D. Reveille;Anne Marie Sims;Patrick Danoy;David M. Evans.
Nature Genetics (2010)
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Michael M. Ward;Atul Deodhar;Elie A. Akl;Andrew Lui.
Arthritis & Rheumatism (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: